Recent Updates
Recently added Catalysts
LTRN Positive Sentiment

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantern Pharma has announced the receipt of a Notice of Allowance from the USPTO for its patent application concerning LP-1284, a drug candidate aimed at treating aggressive B-cell lymphomas, including mantle cell lymphoma. This development marks a significant step in the company's efforts to advance its oncology drug discovery and development initiatives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lantern Pharma received a Notice of Allowance from the USPTO.
  • The patent is for a method to treat aggressive B-cell lymphomas.
  • This approval supports the development of LP-1284 in oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
4%
average across 5 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxel
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284 to treat patients with mantle cell lymphoma (

Frequently Asked Questions

What is the USPTO Notice of Allowance?

It is a notification from the USPTO indicating that a patent application is allowed for issuance.

What is LP-1284 used for?

LP-1284 is a drug candidate aimed at treating aggressive B-cell lymphomas.

What type of cancers does LP-1284 target?

LP-1284 targets blood cancers, specifically mantle cell lymphoma.

Who announced the patent allowance?

Lantern Pharma Inc. announced the USPTO Notice of Allowance.

ShareAdd on Google
Tags: LTRN Viatris Investor Conferences Healthcare Lantern Pharma USPTO LP-1284 B-cell lymphomas oncology
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$7M liquidity · $1M/mo burn
~7 mo
Medium dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxelPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+20%
best trade around LTRN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for LTRN.

See every catalyst's timing & PoA →